Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

South Africa had become a leader in cutting-edge medical research, particularly in HIV and tuberculosis, thanks to years of investment and collaboration. But recent funding cuts by the Trump administration—slashing nearly $50 million in U.S. support—have gutted critical programs, shuttered labs, and left scientists scrambling. The damage threatens not just South Africa’s progress but global health efforts, especially in fighting diseases that disproportionately affect vulnerable populations.

England is bracing for a heatwave as yellow heat health alerts have been issued across most of the country. The warnings highlight potential risks to public health and strain on social care services due to soaring temperatures.

Big Pharma player Eli Lilly is shelling out around $1 billion upfront—with potential payouts reaching $1.3 billion—to snap up Verve Therapeutics, a biotech firm working on cutting-edge treatments for heart disease. This move beefs up Lilly’s pipeline with a promising therapy that could tackle cardiovascular conditions, a massive global health burden.

This piece dives into the latest buzz in the health care sector, spotlighting companies like Hinge Health and Sarepta Therapeutics. It’s a snapshot of market movements, investor chatter, and emerging trends—think of it as a quick pulse check on who’s up, who’s down, and why.

Planning a trip? Don’t forget a well-stocked first-aid kit—it’s your safety net for minor mishaps on the road. Experts recommend basics like bandages, pain relievers, and antiseptic wipes, plus personalized items like allergy meds or motion sickness pills. Their advice? Pack light but smart to keep your adventure smooth and worry-free.

Editor’s Note: Whether you’re hiking mountains or hitting the beach, a little prep goes a long way. This isn’t just about bandaids—it’s about avoiding ruined vacations over preventable snags. A solid first-aid kit is like travel insurance for your health.